Clinical Trial Update: 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

View source ↗

Summary

An 18-month prospective efficacy and safety study of the bimatoprost intracameral implant (DURYSTA) for open-angle glaucoma and ocular hypertension has been com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• DURYSTA (BIMATOPROST)

Snippet

Sponsor: Allergan | Conditions: Open-angle Glaucoma, Ocular Hypertension | Status: COMPLETED